search
Back to results

Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation

Primary Purpose

Hypertensive Phase

Status
Unknown status
Phase
Phase 2
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Timolol-trusopt
placebo
Sponsored by
Zahra Rabbani Khah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertensive Phase focused on measuring hypertensive, phase, success rate, AGV

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients with uncontrolled glaucoma requiring AGV device implantation.

Exclusion Criteria:

  1. History of AGV implantation
  2. Allergy to Anti glaucoma medication
  3. unable to come for follow up
  4. Known contraindication to beta blacker such as asthma- chronic obstructive pulmonary disease (COPD). Heart failure heart block
  5. Learning difficulty- mental illness or severely ill

Sites / Locations

  • Labbafinejad medical centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Timolol-trusopt

placebo,Artificial tear

Arm Description

Dosage:One drop/12hours,duration:3 months

dosage:one drop/12 hours,duration:3 months

Outcomes

Primary Outcome Measures

intraocular pressure-hypertensive phase success rate
during first 3 months

Secondary Outcome Measures

intraocular pressure success rate
after 12 months

Full Information

First Posted
March 7, 2013
Last Updated
March 19, 2013
Sponsor
Zahra Rabbani Khah
Collaborators
Shahid Beheshti University of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01814514
Brief Title
Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation
Official Title
Early Intra Ocular- Pressure Control Using Aqueous Suppressive Agents After Ahmed Glaucoma Valve Implantation
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
March 2013 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Zahra Rabbani Khah
Collaborators
Shahid Beheshti University of Medical Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The AGV implant is designed to open when the IOP is between 8 mmHg and 10 mmHg, and thus maintains an IOP of 8 mmHg or higher. In the early period after glaucoma drainage device (GDD) surgery the intraocular pressure (IOP) classically goes through 2 phases. The hypotensive phase occurs immediately after surgery, lasts around 1 week. This is followed by the hypertensive period where the IOP tends to rise steadily above 21mmhg. The hypertensive response seems to occur more commonly after Ahmed GDD surgery than nonvalved implants, It was reported to occur in 40% to 80% of cases. Although the hypertensive phase can last as long as 6 months it is usually during the first 1 to 4 weeks, when there is intense congestion of the bleb wall, that IOP is highest. Previous study showed that when aqueous comes into contact with conjunctiva and Tenon's capsule,an inflammatory reaction occurs.Factors such as prostaglandins, eicosanoids, tissue growth factor beta (TGF β)has been shown to occur in glaucomatous aqueous. These mediators induce an inflammatory reaction, and if excessive, will result in fibrosis and poor functioning of the bleb. High pressure within the bleb also results in the secretion of TGF β by the bleb lining. It may result in inflammation of the bleb wall and subsequent fibrosis and poor bleb function. The investigators supposed that with early use of aqueous suppressant medication after AGV implantation, the concentration of inflammatory mediators decreased in subconjunctival space and may lead to better IOP control after shunt surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertensive Phase
Keywords
hypertensive, phase, success rate, AGV

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
94 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Timolol-trusopt
Arm Type
Active Comparator
Arm Description
Dosage:One drop/12hours,duration:3 months
Arm Title
placebo,Artificial tear
Arm Type
Placebo Comparator
Arm Description
dosage:one drop/12 hours,duration:3 months
Intervention Type
Drug
Intervention Name(s)
Timolol-trusopt
Other Intervention Name(s)
cosopt
Intervention Type
Drug
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
intraocular pressure-hypertensive phase success rate
Description
during first 3 months
Time Frame
during first 3 months
Secondary Outcome Measure Information:
Title
intraocular pressure success rate
Description
after 12 months
Time Frame
after 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients with uncontrolled glaucoma requiring AGV device implantation. Exclusion Criteria: History of AGV implantation Allergy to Anti glaucoma medication unable to come for follow up Known contraindication to beta blacker such as asthma- chronic obstructive pulmonary disease (COPD). Heart failure heart block Learning difficulty- mental illness or severely ill
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohammad pakravan, Associate Professor
Email
labbafi@hotmail.com
Facility Information:
Facility Name
Labbafinejad medical center
City
Tehran
Country
Iran, Islamic Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohammad Pakravan, Associate Professor
Email
labbafi@hotmail.com
First Name & Middle Initial & Last Name & Degree
Mohammad Pakravan, Associate Professor

12. IPD Sharing Statement

Learn more about this trial

Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation

We'll reach out to this number within 24 hrs